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Abstract: Mice with reconstituted human immune systems can mount cell-mediated immune responses
against the human tumor viruses Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus
(KSHV). Primarily cytotoxic lymphocytes protect the vast majority of persistently infected carriers of
these tumor viruses from the respective malignancies for life. Thus, EBV and KSHV infection can teach
us how this potent immune control is induced, what phenotype and functions characterize the protective
lymphocyte compartments and if similar immune responses could be induced by vaccination. This review
will summarize similarities and differences between EBV and KSHV associated pathologies and their
immune control in patients and mice with reconstituted human immune systems. Furthermore, it will
high-light which aspects of the near perfect immune control can be modeled in the latter preclinical
animal models and discuss their relevance for cancer immunology in general.
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Mice with reconstituted human immune systems can mount cell-mediated immune
responses against the human tumor viruses Epstein Barr virus (EBV) and Kaposi
sarcoma associated herpesvirus (KSHV). Primarily cytotoxic lymphocytes protect the
vast majority of persistently infected carriers of these tumor viruses from the respective
malignancies for life. Thus, EBV and KSHV infection can teach us how this potent
immune control is induced, what phenotype and functions characterize the protective
lymphocyte compartments and if similar immune responses could be induced by
vaccination. This review will summarize similarities and differences between EBV and
KSHV associated pathologies and their immune control in patients and mice with
reconstituted human immune systems. Furthermore, it will high-light which aspects of
the near perfect immune control can be modeled in the latter preclinical animal models
and discuss their relevance for cancer immunology in general.
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INTRODUCTION ON EBV AND KSHV SPECIFIC IMMUNE
CONTROL
The two human γ-herpesviruses Epstein Barr virus (EBV) and Kaposi sarcoma associated
herpesvirus (KSHV) are WHO class I carcinogens (1–3). They are associated with lymphomas,
Hodgkin’s and Burkitt’s in the case of EBV, and primary effusion lymphoma (PEL), andmulticentric
Castleman’s disease (MCD) for KSHV (4). Furthermore, EBV causes epithelial cell tumors, like
nasopharyngeal and 10% of gastric carcinoma (5), while KSHV is the etiological cause of the
endothelial cell derived cancer Kaposi sarcoma (3). Fortunately, these malignancies are rare with
incidence rates of less than 1 in 104 individuals, even so more than 95% of the human adult
population is persistently infected with EBV, and more than 50% of the Sub-Saharan African
population with KSHV (3, 6). However, EBV and KSHV associated lymphomas as well as Kaposi
sarcoma develop at increased frequencies after immune suppression, due to for example human
immunodeficiency virus (HIV) infection or iatrogenic treatment after transplantation (7, 8).
Moreover, primary immunodeficiencies, often caused by individual genemutations, can predispose
for EBV and KSHV associated diseases (9). Interestingly, the affected genes point toward well
defined immune compartments that control EBV and KSHV infection and prevent associated
malignancies in most virus carriers. Even so EBV and KSHV are closely related γ-herpesviruses, the
requirements for their immune control seem to be quite dissimilar. Primary immunodeficiencies
that predispose for EBV associated diseases affect the cytotoxic machinery of lymphocytes,
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including natural killer (NK) and CD8+ T cells (10, 11).
In addition, co-stimulatory molecules on these cytotoxic
lymphocytes, like CD27, 4-1BB, 2B4, and NKG2D, seem to be
required to control EBV. A third group of molecules that are
required for EBV specific immune control, are involved in T cell
receptor signaling, such as interleukin-2 inducible T cell kinase
(ITK), ZAP70, and PI3K. Finally, gene products that support
and sustain cytotoxic lymphocyte development and expansions,
like MCM4, CTPS1, and XIAP, are required for EBV specific
immune control. Surprisingly, type I and II interferons (IFNs)
as well as antibody responses are dispensable for the immune
control of EBV (11). In contrast, type II IFN signaling with IFN-γ
receptor 1 and STAT4 protects from Kaposi sarcoma (9, 12). In
addition, OX40 instead of the above mentioned co-stimulatory
molecules is required to protect from Kaposi sarcoma (13). Thus,
primary immunodeficiencies suggest that cytotoxic lymphocytes
keep persistent EBV infection in check, while their cytokine
production protects in addition from KSHV. Accordingly, these
two pathogens are suitable to challenge human immune systems
with their tumorigenic potential and test their robustness in
raising cell-mediated immune responses.
VIRUS ASSOCIATED MALIGNANCIES
Such challenges are for example applied to immune
compromised mice with reconstituted human immune system
components, such as NOD-scid γc
−/− that are neonatally
injected with human CD34+ hematopoietic progenitor cells
(HPCs) and then develop human leucocytes during three to
6 months (humanized mice) (14, 15) (Figure 1). In order,
however, to explore the protective capacity of the reconstituted
human immune system compartments, at least some of the
EBV and KSHV associated pathologies must be recapitulated
in these humanized mouse systems. Accordingly, the viral gene
expression patterns have been analyzed after EBV infection of
humanized mice (16–21). In most of these studies a high dose of
infectious viral particles from the B95-8 EBV strain, originally
isolated during symptomatic primary infection called infectious
mononucleosis (IM), was used. As in secondary lymphoid
tissues, including tonsils, of IM patients (22) primarily EBV
infected B cells expressing the latency III infection program
with six nuclear antigen (EBNA1, 2, 3A-C, and LP), two latent
membrane proteins (LMP1,2) as well as non-translated EBER
and viral miRNAs, were observed (21). In addition, however,
low levels of latency I and II with EBNA1 as the sole or in
addition LMP1 and 2 protein expression could be detected (18,
23). Low levels of these lower latencies were also verified by
detection of characteristic viral transcripts (21, 24, 25). While
latency III is found in naïve B cells of healthy EBV carriers,
latency II predominates in germinal center B cells and latency
I in homeostatically replicating memory B cells (26, 27). It
is unclear if the respective latencies are also in similar B cell
differentiation stages in humanized mice. In humans, EBV
persists without viral protein expression in circulating memory B
cells of so-called latency 0 (28). This latency 0 can also be reached
in humanized mice (20). From latency 0 and I EBV switches into
lytic replication upon plasma cell differentiation in healthy virus
carriers (29). Such reactivation only rarely occurs with the B95-8
EBV virus in humanized mice (30), but other viruses such as
the M81 EBV strain are more prone to lytic replication (31, 32).
In contrast to these IM-like infections, lower viral doses might
mimic asymptomatic primary infection, as it occurs in the vast
majority of humans (6), but these have so far not extensively
been explored in humanized mice (33). Nevertheless, all EBV
infection programs can be found upon usually intraperitoneal
inoculation of humanized mice.
According to the predominance of EBV latency III infection
the virus-associated lymphomas that develop in up to one third
of infected mice also carry this strongly growth transforming
gene expression program akin to some diffuse large B cell
lymphomas (DLBCL) and in vitro EBV transformed, B cell
derived lymphoblastoid cell lines (LCLs) (2). Burkitt’s and
Hodgkin’s lymphomas that carry latency I and II have so far
not been reported. DLBCL-like lymphomagenesis can further be
increased by infection with an EBV strain that is deficient in
the viral tumor suppressor EBNA3B (34). Accordingly, EBNA3B
loss has also be found in a subset of DLBCLs in human patients
(34, 35). Furthermore, both EBV and KSHV are present in
most PELs (36). Of all KSHV associated malignancies PEL cells
are also the only one that maintains KSHV in culture (37).
Interestingly, KSHV infection only persists in humanized mice
upon co-infection with EBV (23, 38). Similarly, both viruses or
their monkey orthologues seem to be co-transmitted in both
macaques and humans (39, 40). Furthermore, EBV supports
KSHV infection of B cells in vitro (41). KSHV and EBV co-
infection of humanized mice also allows for the development of
PEL-like lymphomas (Figure 1) with characteristics of plasma
cell differentiation that have previously been defined for PELs
(23, 42). Consistent with lytic EBV replication being associated
with plasma cell differentiation (29) both PEL-like tumors in
humanized mice and human PELs displayed elevated lytic viral
gene products and this lytic EBV replication contributed to
enhanced tumor formation in double-infected humanized mice
(23). Thus, EBV associated DLBCLs and KSHV as well as EBV
positive PELs can be elicited in humanized mice.
IMMUNE CONTROL BY INNATE
LEUKOCYTES
The symptomatic primary EBV infection IM is an
immunopathology caused by massive expansion of CD8+
T cells that are predominantly directed against lytic EBV antigens
(43). This disease is rare in children but can make up 30 to 50% of
primary infections in adolescents (6). Therefore, EBV infection
at young age seems to trigger a different immune response than
later in life. One reason for this altered immune response could
be more robust innate immune control of lytic EBV infection in
children. Along these lines it has been shown that NK cells protect
from lytic EBV infection in humanized mice (19, 44) (Figure 1).
In both humanized mice and pediatric IM patients primarily
early differentiated CD56dimNKG2A+killer immunolglobulin-
like receptor (KIR)− NK cells expand (19, 45–48). While these
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FIGURE 1 | Challenging humanized mice with EBV and KSHV infection. Mice with reconstituted human immune system compartments (humanized mice) are
generated by injecting human CD34+ HPCs into immune compromised mice, such as the NOD-scid γc
-/- mouse strain. After 3 months humanized mice can be
infected with EBV with and without KSHV. Persistent infection with these two viruses develops into PEL-like lymphomas after double infection after 4 weeks (wks),
EBV lytic replication can be observed after 3 weeks and DLBCL-like lymphomas develop after 5–6 weeks. While the immune control of KSHV in humanized mice still
needs to be defined, NK and αβ T cells control lytic EBV replication, and NKT, γδ T and αβ T cells prevent DLBCL-like tumorigenesis by targeting latent EBV infection.
This figure was created in part with modified Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 unported license:
https://smart.servier.com.
are the most abundant NK cell subpopulation after birth in
humans, they differentiate to CD56dimNKG2A−KIR+ NK cells
during the first decade of life (45), possibly rendering adolescents
more susceptible to IM. It has been suggested that ligands
for the activating NK cell receptors NKG2D and DNAM1 get
up-regulated on B cells that undergo lytic EBV reactivation,
and that NKG2D and DNAM1 mediate NK cell cytotoxicity
against the respective targets (49). Thus, NK cell differentiation
could diminish protective NK cell populations during the first
decade of life, compromising innate immune control of lytic EBV
infection which in turn would trigger the massive expansion of
lytic EBV antigen specific CD8+ T cells, causing IM.
However, in addition to NK cells other innate lymphocyte
populations might play a role during EBV infection. Along these
lines it has been shown that Vγ9Vδ2 T cells that recognize
mevalonate metabolism intermediates presented by butyrophilin
2A1 (BTN2A1) prevent EBV associated lymphoproliferative
disease in humanizedmice (50). Similarly, the transfer of Vγ9Vδ2
T cells inhibited tumor growth in EBV transformed B cell
carrying mice (51). Vγ9Vδ2 T cells recognized EBV infected B
cells by their T cell receptor and NKG2D as a co-receptor (50).
Especially EBV latency I Burkitt’s lymphoma cell lines expanded
human Vγ9Vδ2 T cells (52). These lymphoma cell lines displayed
the highest levels of mevalonate metabolite presentations on
BTN2A1. Interestingly, only around 50% of human individuals
could raise these protective Vγ9Vδ2 T cell responses against
EBV infected targets (52). These so-called group 1 individuals
harbor a high frequency of Vγ9Vδ2 T cells with T cell receptors
that utilize JγP segments (53). These Vγ9JγP T cells expanded
upon stimulation with Burkitt’s lymphoma cell lines. Thus,
Vγ9Vδ2 T cells might protect preferentially against EBV latency
I infected B cells.
Finally, there might also be a role for NKT cells that recognize
glycolipid presentation on CD1d non-classical MHC class I
molecules (54, 55). Adoptive transfer of NKT cells into mice that
carried EBV transformed B cells reduced their tumor formation
(54). They seemed to recognize freshly EBV infected B cells
and EBV latency II infected tumor cells, while CD1d is down-
regulated on EBV latency III infected B cells (55). Along these
lines, X-linked lymphoproliferative (XLP-1) disease which affects
primarily boys due to mutations in the 2B4 adaptor SAP and
which confers life-threatening susceptibility to EBV associated
pathogenesis, lack NKT cells (56). Thus, NKT cells might also
contribute to innate immune control of latently EBV infected B
cells, possibly preferentially expressing the latency II program.
Humanized mice have contributed to demonstrate immune
control by NK, Vγ9Vδ2 T cells, and NKT cells against lytic and
latent EBV infected B cells, respectively. Only fully transformed
EBV latency III B cells, resembling DLBCLs, do not seem to be
efficiently recognized by innate lymphocytes, but these seem to
target EBV infected precursors that are required for DLBCL-like
tumor development in humanized mice (Figure 1).
Frontiers in Immunology | www.frontiersin.org 3 September 2020 | Volume 11 | Article 581419
Münz EBV and KSHV in huMice
CYTOTOXIC T CELL RESPONSES
In contrast to innate lymphocytes, EBV latency III infected B
cells that can be also generated in vitro by EBV infection of
human B cells, are highly immunogenic for T cells. Indeed,
adoptive transfer of LCL stimulated T cell lines into patients
with EBV induced post-transplant lymphoproliferative disease
(PTLD) was one of the first cellular therapies and was able to
cause PTLD regression (57). The EBV antigens EBNA1, LMP1,
and LMP2 have proven to be sufficient as T cell targets for
such adoptive T cell transfer therapies against EBV associated
malignancies (58, 59). Similarly in humanized mice antibody
mediated T cell depletion increased EBV viral loads and DLBCL-
like lymphomagenesis (16, 60) (Figure 1). While primarily CD8+
T cells seemed to protect from EBV induced lymphomagenesis in
humanized mice, antibody depletion, pharmacological inhibition
by FK506 or destruction of CD4+ T cells by HIV co-infection
also compromised EBV specific immune control in humanized
mice (16, 21, 25). Along these lines, late lytic EBV antigen specific
CD4+ T cells have been reported to restrict EBV transformed B
cell growth in mice (61). Thus, both cytotoxic CD8+ T cells and
helper T cell functions seem to be required for adaptive immune
control of EBV in humanized mice.
Antibody blocking and recombinant EBV mutant infection
experiments have revealed crucial aspects of this T cell mediated
immune control of EBV in humanized mice and helped to
explain the mechanistic underpinnings of EBV susceptibility in
patients with the above mentioned primary immunodeficiencies.
Among the co-stimulatory molecules, blocking of 2B4, one of
the receptors that depends on SAP for activating signaling
and is affected in XLP-1, led to increased EBV loads and
lymphomagenesis (62). This 2B4 requirement was mainly on
CD8+ T cells because their antibody mediated depletion did
not further increase viral titers and tumor formation. In
addition, CD8+ T cells with the inhibitory co-receptor PD-
1 expanded during IM and in EBV infected humanized mice
(33, 63). They included both latent (LMP2) and lytic (BMLF1)
EBV antigen specific CD8+ T cells. These PD-1 positive
CD8+ T cells carried the highest cytotoxic ability during EBV
infection of humanized mice. Furthermore, they expressed
CXCR5, Tim-3, KLRG1, and TCF-1 (33) and resembled germinal
center homing CD8+ T cells which have previously been
described to contain EBV specific CD8+ T cells in human
tonsils (64). Interestingly, antibody blocking of PD-1 led to
increased EBV viral loads and lymphomagenesis. This was
associated with IL-10 production and might therefore represent
activation of a regulatory CD4+ T cell population during PD-
1 inhibition that compromises EBV specific immune control.
Along these lines, at least a subset of patients that undergo
PD-1 blockade for tumor treatment and develop neurological
side effects, have recently been shown to harbor elevated
EBV loads and accumulate EBV infected B cells and EBV
reactive CD4+ and CD8+ T cells in their central nervous
system (65). In contrast to PD-1 blockade on regulatory
CD4+ T cells, humanized mouse models that sustained only
T and EBV transformed B cell reconstitution developed
exhausted, presumably CD8+ T cell populations and antibody
blocking of their PD-1 and CTLA-4 inhibitory receptors
restored EBV specific immune control (66). Antibody blocking
studies have, therefore, suggested essential roles for PD-
1, CTLA-4, and 2B4 during EBV specific immune control
in humanized mice.
Additional characteristics of protective EBV specific T
cell responses have been revealed by recombinant EBV
mutant viruses. In addition to secondary lymphoid tissue
homing, CXCR3 dependent T cell homing to inflamed tissues
has been found to be critical for immune control of EBV
in humanized mice by studying EBNA3B deficiency (34).
EBNA3B deficiency which was observed in some patients
with DLBCL (34, 35), elicited elevated lymphomagenesis in
humanized mice (34). The respective tumors were devoid
of T cell infiltrates and EBNA3B deficient LCLs were found
to produce less of the CXCR3 stimulating CXCL9 and 10
chemokines. Transgenic CXCL10 expression by EBNA3B
deficient LCLs restored their T cell mediated immune control
in vivo. In addition, compromised MHC class I antigen
presentation by EBV miRNAs limits EBV specific immune
control (67). miRNA deficient EBV did not induce any
DBLCL-like lymphomas in humanized mice, but tumor
formation was restored upon antibody mediated CD8+ T
cell depletion. Both latent and at least early lytic CD8+ T
cell responses might contribute to CD8+ T cell mediated
immune protection against EBV associated lymphomagenesis
in humanized mice (18, 30). EBV deficient in the immediate
early lytic EBV transactivator BZLF1 was compromised in
its ability to cause DLBCL-like lymphomas in humanized
mice, KSHV co-infection increased lytic EBV replication
and lymphomagenesis, and BMLF1 specific CD8+ T cells
were able to transiently control lytic EBV infection after
their adoptive transfer (18, 23, 30). These studies define
CXCR3 dependent homing, targeting of early lytic EBV
antigens and efficient MHC class I antigen presentation
as additional characteristics of EBV specific immune
control by T cells.
In contrast to CD8+ T cells, CD4+ T cells can, however,
also mediate pro-tumorigenic effects. LMP1 deficient EBV
required CD4+ T cells for DLBCL-like lymphoma formation
in humanized mice (68). Furthermore, CD4+ T cells allowed
EBV to access the Burkitt’s and Hodgkin’s lymphoma associated
EBV latencies I and II in humanized mice, even so no tumors
with these viral gene expression patterns have so far been
observed in any humanized mouse model (24). Therefore,
both anti- and pro-tumorigenic functions of T cells can be
studied during EBV infection of humanized mice, and so far,
CXCR3+CXCR5+2B4+CD8+ T cells have emerged as the main
protective entity.
VACCINATION
Epstein Barr virus specific immune control is uniquely dependent
on cell mediated immunity and cytotoxic lymphocytes, while
individuals with deficient antibody responses do not suffer
from EBV associated pathologies (9–11). This cytotoxic immune
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control of EBV can be recapitulated in humanized mice (14).
Therefore, humanized mice should be well suited to test EBV
specific vaccine candidates and develop vaccines that efficiently
prime cytotoxic lymphocytes and are also required to stimulate
other anti-tumor immune protection (69). Unfortunately, it has
been quite frustrating to identify vaccine candidates that manage
to induce such protective T cell responses. Antigen targeting to
dendritic cells (DCs), recombinant viral vectors, and virus like
particles (VLP) have been explored.
Even so EBNA1 specific T cells have been therapeutically
used against PTLD (58) and this antigen is incorporated in
many vaccine formulations (70–74), targeting of EBNA1 to
DCs and uptake via their DEC-205 receptor has elicited only
weak CD4+ T cell responses (75, 76). However, even in
regular mice this vaccine formulation was even with a boost
by a recombinant adenovirus encoding EBNA1 less efficient
in inducing T cell responses than heterologous prime-boost
vaccination with EBNA1 encoding adenovirus and modified
vaccinia virus Ankara (MVA) (74). In contrast, an EBV derived
VLP into which EBNA1 was incorporated as a tegument
component elicited protective CD4+ T cell responses against
EBV challenge in humanized mice (77). This VLP targets
B cells as EBV does, and the abundance of these antigen
presenting cells (APCs) in humanized mice could facilitate the
priming of sufficient numbers of protective T cells. Similarly,
yellow fever virus (YFV) specific vaccination that is based
on the attenuated viral strain YFV17D required human DC
expansion prior to YFV17D injection to prime significant T cell
responses (78). Such expanded APC populations, as exemplified
by the high constitutive B cell reconstitution in humanized
mice and Flt3L mediated DC expansion might overcome
the paucity in secondary lymphoid tissue development that
most humanized mouse models suffer from (79). Interestingly,
adoptive transfer of DC populations did not only increase these
APC populations and allowed for more efficient induction of
human cytomegalovirus (HCMV) specific immune responses in
humanized mice, but also induced the formation of secondary
lymphoid tissues like lymph nodes (80). These structures then
did not only facilitate the priming of T cell, but also antibody
responses (80). Thus, humanized mice allow for the evaluation
of vaccines, but might require expansion of APC populations
and secondary lymphoid tissues for them to meet naïve T cells
for adaptive cell-mediated and possibly even humoral immune
response induction.
CONCLUSION AND OUTLOOK
Humanized mice hold the promise that human immune
responses and their modulation by immunotherapies as well
as vaccinations can be studied. However, at least humoral
immune responses are severely attenuated in these mice and
mucosal immune reconstitution is only rudimentary. As a
result, only few pathogens have been shown to elicit protective
immune responses in humanized mouse systems. As these
models get further improved by introduction of human MHC
and cytokine genes, as well as additional human organoids (15)
immunocompetence will probably increase. However, already
with the available models strongly T cell immunogenic pathogens
like EBV and KSHV can be characterized for their infection,
tumorigenesis, and cell-mediated immune control. Indeed, EBV
is the pathogen that most often leads to even pathogenic
CD8+ T cell expansions in humans, as in IM, and primary
immunodeficiencies as well as therapeutic adoptive T cell transfer
suggest that such cytotoxic lymphocyte responses are necessary
and sufficient for its immune control (9, 43, 81). This suggests
that EBV is well suited to interrogate the immunocompetence
of cytotoxic lymphocyte compartments in humanized mice and
should be able to reveal improvements of these preclinical
in vivomodels.
At the same time anymanipulation of T cell mediated immune
control, like immune checkpoint inhibition, can be assessed
for its ability to improve or compromise EBV specific immune
control, even if the respective treatments are developed for other
tumors than EBV associated malignancies. The influence of these
treatments on EBV infection should still be of interest because the
vast majority of adult humans (>95%) are persistently infected
with EBV (2) and, therefore, any immune modulation of anti-
tumor T cell responses will also affect EBV specific immune
control in the respective patients, as becomes apparent during
immunosuppressive treatment after transplantation, increasing
the risk for PTLD (7, 21). Thus, EBV infected humanized mice
constitute an interesting preclinical in vivo system to test human
immune modulators.
Finally, it remains difficult to construct humanized mice
with tumors and long-term engraftment of diverse autologous
human immune system components (15). However, the growth
transforming ability of EBV allows for the generation of
autologous tumor cells that can be genetically manipulated
and afterward implanted into humanized mice that have
been reconstituted with CD34+ HPCs from the same donor.
Therefore, it is one of the few systems that currently allow
studying tumor interaction with human immune system
components in an autologously xenografted humanized mouse
model. All these advantages should allow us to interrogate
human immune responses and design vaccines as well as other
immunotherapies to elicit them more comprehensively.
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